DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:55:15 10/06/2024 pm IST | ||
| 229.28 EUR / 230.65 EUR | +0.63% |
|
| Current month | +0.70% | ||
| 1 month | +0.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 229.6 | +0.49% |
| 07/24/07 | 228.5 | +0.75% |
| 06/24/06 | 226.8 | -0.18% |
| 05/24/05 | 227.2 | +0.24% |
| 04/24/04 | 226.7 | +0.14% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 03:27 pm IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME8J13 |
| ISIN | DE000ME8J138 |
| Date issued | 09/02/2024 |
| Maturity | 20/12/2024 (193 Days) |
| Parity | 1 : 1 |
| Emission price | 224.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 229.6 € |
|---|---|
| Lowest since issue | 221.4 € |
| Spread | 1.37 € |
| Spread % | 0.59% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
